以下部分引用 AI 总结，现阶段 AI 仍然有幻觉。请以内容的原文为准。

数据新鲜度群聊 07-14 ✓卖方 07-14 ✓Wrap 断档15天 ✕News 07-15 ✓X 断档12天 ✕页面生成 07-15

SRPT

9 atoms · 跨 2 天 · 首见 2026-04-17 · 最近 2026-06-30

三色: 🟦 fact 4 · 🟥 take 5 · stance ▲3/▼5/◆0

来源: X 9

时态: fresh:7 · aging:2

标签: 好观点:3 · 好数字:3 · 好信源:3

2026-06-30 · FDA sNDA acceptance for two DMD drugs is positive, de-risking event
Analyst sees FDA's sNDA acceptance for two DMD drugs as a positive, de-risking event given past trial data concerns
tags: 好观点 · → daily
2026-04-17 [老化中] · 评级
$SRPT | 𝐒𝐚𝐫𝐞𝐩𝐭𝐚: H.C. Wainwright reiterates 𝐒𝐞𝐥𝐥, maintains 𝐏𝐓 𝐚𝐭 $𝟓
tags: 好观点 · → daily
value: qty=Sell
2026-04-17 [老化中] · ELEVIDYS美国业务
limited upside and significant downside to core U.S. ELEVIDYS franchise
tags: 好观点 · → daily

2026-04-17 · 目标价
$SRPT | 𝐒𝐚𝐫𝐞𝐩𝐭𝐚: H.C. Wainwright reiterates 𝐒𝐞𝐥𝐥, maintains 𝐏𝐓 𝐚𝐭 $𝟓
tags: 好数字 · → daily
value: qty=$5

2026-06-30 · Mizuho reiterates Outperform
Mizuho reiterates 𝐎𝐮𝐭𝐩𝐞𝐫𝐟𝐨𝐫𝐦 on 𝐒𝐚𝐫𝐞𝐩𝐚, maintains 𝐏𝐓 𝐚𝐭 $𝟑𝟏 following 𝐩𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐅𝐃𝐀 𝐧𝐞𝐰𝐬
tags: 好信源 · → daily

2026-06-30 · FDA 接受传统批准申请
the FDA accepted applications to convert AMONDYS 45 and VYONDYS 53 from accelerated approval to traditional approval. PDUFA date: Feb. 28, 2027.
tags: 好信源 · → daily
value: date=2027-02-28
2026-06-30 · ESSENCE 未达主要终点
ESSENCE did not meet its primary endpoint.
tags: 好信源 · → daily
2026-04-17 · 当前股价
当前股价 (Current Price): $21.17; 下行空间 (Downside): -76.4%
tags: 好数字 · → daily
value: qty=$21.17
2026-04-17 · 下行空间
当前股价 (Current Price): $21.17; 下行空间 (Downside): -76.4%
tags: 好数字 · → daily
value: qty=-76.4%

2026-06-30 · fact · FDA 接受传统批准申请 · → daily
2026-06-30 · fact · ESSENCE 未达主要终点 · → daily
2026-06-30 · position · Mizuho reiterates Outperform · → daily
2026-06-30 · narrative · FDA sNDA acceptance for two DMD drugs is positive, de-riskin · → daily
2026-04-17 · narrative · 评级 · → daily
2026-04-17 · forecast · 目标价 · → daily
2026-04-17 · fact · 当前股价 · → daily
2026-04-17 · fact · 下行空间 · → daily
2026-04-17 · narrative · ELEVIDYS美国业务 · → daily